Arrowstreet Capital Limited Partnership Has $14.57 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Arrowstreet Capital Limited Partnership increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 131.4% during the 4th quarter, Holdings Channel reports. The fund owned 698,152 shares of the biopharmaceutical company’s stock after buying an additional 396,506 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Catalyst Pharmaceuticals were worth $14,570,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC grew its stake in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $65,000. KBC Group NV raised its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $134,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $23.07 on Friday. The stock has a 50 day moving average price of $22.78 and a 200 day moving average price of $21.94. The stock has a market capitalization of $2.80 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16.

Analysts Set New Price Targets

Several analysts have commented on CPRX shares. Bank of America restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens reaffirmed an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.